Protara Therapeutics TARA
NASDAQ TARA
$2.62 +0.19 (+7.82%)
At close: Nov 11, 2026 · 4:00 PM EST

Protara Therapeutics (TARA) Gains from Sales and Divestitures (2013)

Updated

Protara Therapeutics (TARA) reported Gains from Sales and Divestitures of $58,000 for Q4 2013.

Analysis

Protara Therapeutics (TARA) Gains from Sales and Divestitures (2013) Analysis & Trends

For FY2013, Protara Therapeutics posted Gains from Sales and Divestitures of $65,000.

  • By year, Gains from Sales and Divestitures came in at $5,000 in FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Protara Therapeutics 149.62 Mn -411.27 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2013 58,000.00
API Access

Protara Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=TARA&period=max&api_key=YOUR_API_KEY